cefepime hydrochloride

Phase 1Small molecule

JJonsson Comprehensive Cancer Center

cefepime hydrochloride is one of 40 small molecule programs targeting Neutropenia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeutropeniaActive, not recruiting

NeutropeniaPhase 1

Active, not recruiting

Competition

Competitive Landscape

124 competitors in Neutropenia

#DrugCompanyPhaseTrials

Cubicin

BBaxter Healthcare Corporation

Phase 3

3 2

Mycostatin

GGood Molecules, LLC

Phase 3

1 3

Caspofungin Acetate

Merck & Co.

Phase 3

4 4

Amphotericin B Deoxycholate

Merck & Co.

Phase 3

1 5

Liposomal Lurtotecan

Gilead

Phase 3

1 6

Alcohol

Ellence

1 8

Cytosar

Teva

Phase 2

1 9

Medrol

Pfizer

Phase 2

1 10

G-CSF

AArog Pharmaceuticals, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neutropenia2 trials

Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

Completed·WWake Forest University Health Sciences·Phase 1·NCT01484015·70 enrolled

Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia

Unknown status·JJonsson Comprehensive Cancer Center·Phase 3·NCT00020865

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for cefepime hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cefepime hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cefepime hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jonsson Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJonsson Comprehensive Cancer Center

cefepime hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neutropenia2 trials

References

Drug Info

Quick Facts

Related News